EXPRESSION OF THE GANGLIOSIDES GM3, GD3 AND GD2 IN TISSUE-SECTIONS OF NORMAL SKIN, NAEVI, PRIMARY AND METASTATIC MELANOMA
EXPRESSION OF THE GANGLIOSIDES GM3, GD3 AND GD2 IN TISSUE-SECTIONS OF NORMAL SKIN, NAEVI, PRIMARY AND METASTATIC MELANOMA
复制标题
DOI：
10.1002/ijc.2910410303
复制
发表时间：
1988-03-15
影响因子：
6.4
通讯作者：
DALESSANDRO, G
中科院分区：
文献类型：
--
作者：
HERSEY, P;JAMAL, O;DALESSANDRO, G
应用ABC免疫组织化学技术对19例色素痣、29例原发黑色素瘤和83例转移性黑色素瘤组织切片中神经节苷脂GM3、GD3和GD2的表达进行了研究。GM3在正常皮肤中未检测到，而GD2在真皮的基底层和棘层以及真皮的周围神经中均可检测到。GD3在黑素细胞上表达，但在正常皮肤的大多数其他成分上不表达。与正常皮肤相比，GD2在26/29例原发性黑色素瘤组织中不表达。除结合部未检测到GM3外，其余血管内皮细胞均为GM3和GD3阳性。除神经样分化的区域外，GD2在痣上不表达。对黑色素瘤的研究表明，大约60%的原发黑色素瘤和75%的转移性黑色素瘤不同程度地表达GM3。除了两个例外，所有原发和GD2仅在大约25%的原发黑色素瘤和50%的转移性黑色素瘤中检测到。黑色素瘤周围淋巴细胞表达GD2和GD3。GD2在转移性黑色素瘤中的表达高于原发黑色素瘤，这与GD2表达与转移潜能增加有关的观点是一致的。然而，CD2表达的转移率较低，且与原发灶厚度无相关性，提示GD2的表达不是转移潜能的可靠标记物。神经节苷脂在皮肤和淋巴结转移灶中的表达差异无统计学意义。这些结果似乎对在黑色素瘤的治疗和黑素细胞分化的研究中使用抗神经节苷脂的单抗有一定的意义。
Expression of the gangliosides GM3, GD3 and GD2 was studied in tissue sections from 19 naevi, 29 primary and 83 metastatic melanoma using the ABC immunoperoxidase technique. GM3 was not detected in normal skin whereas GD2 was detected on the basal and stratum spinosum of the epidermis and on peripheral nerves in the dermis. GD3 was expressed on melanocytes but not on most other components of normal skin. However, GD3 was strongly expressed on epidermis adjacent to naevi and primary melanoma whereas GD2, in contrast to that in normal skin, was not expressed on the epidermis adjacent to 26/29 primary melanoma. All naevi were positive for GM3 and GD3 except that GM3 was not detected on junctional components of naevi. GD2 was not expressed on naevi except in areas showing neuroid differentiation. Studies on melanoma revealed that approximately 60% of primary and 75% of metastatic melanoma expressed GM3 to a varying extent. With 2 exceptions, all primary and GD2 was detected in only approximately 25% of primary and 50% of metastatic melanomas. Both GD2 and GD3 were detected on lymphocytes surrounding melanoma. The higher expression of GD2 on metastases compared to primary melanomas was consistent with the view that GD2 expression was associated with increased metastatic potential. However, the low proportion of metastases expressing CD2 and the absence of any correlation with thickness of the primary tumour suggested that GD2 expression was not a reliable marker of metastatic potential. No differences could be detected in ganglioside expression on metastases in skin or lymph nodes. These results appear to have implications for the use of MAbs against gangliosides in therapy of melanoma and in the study of melanocytic differentiation.